Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.

Sai-Hong I Ou,Huamao M Lin,Jin-Liern Hong,Yu Yin,Shu Jin,Jianchang Lin,Minal Mehta,Pingkuan Zhang,Danny Nguyen,Joel W Neal

Lung cancer (Amsterdam, Netherlands)（2023）

引用 0|浏览20

暂无评分

摘要

Mobocertinib showed substantially improved outcomes versus an external control group using available therapies in platinum-pretreated patients with EGFR ex20ins-mutant NSCLC. In the absence of comparative evidence from randomized trials, these findings help elucidate potential benefits of mobocertinib in this rare population.

查看译文

关键词

Comparative evidence,EGFR exon 20 insertion,External control,Indirect comparison,Mobocertinib,Propensity-score matching,Real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要